CMU Professor Yi-Wen Chen Receives the “2021 Future Technology Award” with Her Team’s Development of a Precision Drug Screening Platform
Date：September 6, 2021
The cross-university research team of the multi-dimensional printing research and translational center led by Professor Yi-Wen Chen (Graduate Institute of Biomedical Sciences), has developed the first screening platform for patients’ in vitro oncology drugs that successfully makes use of Taiwan’s clinical resources and cross-field cooperation. The platform, that Biofabricates the patient-specific tumor-on-a-chip system for medical predictions, provides doctors with accurate diagnosis and guidelines for more precise prediction of treatments. This not only benefits cancer patients, but also demonstrates the outstanding strength of Taiwan’s biomedical technology. As a result of their work, the team was awarded the 2021 Future Technology Award.
The new platform focuses on applying the tumor cells of patients to establish the in vitro tumor characteristics and micro-environment similar to that of the patient’s body, and accurately testing the effect of cancer drugs on tumor cells in the 3D tumor-like sphere chips that meet the in vitro physiological conditions.
In terms of clinical research, Professor Chen’s team is also cooperating with the lung cancer research team of China Medical University Hospital. They have found many research results relevant to clinical application and provided doctors with more possibilities to prescribe medication and more effective treatment.